ravuconazole profile

ER 30346: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ravuconazole : A member of the class of triazoles that is 1-butyl-1H-1,2,4-triazole in which the butyl group is substituted at positions 2, 2, and 3 by hydroxy, 2,4-difluorophenyl, and 4-(p-cyanophenyl)-1,3-thiazol-2-yl groups, respectively (the R,R stereoisomer). It exhibits antifungal activity by inhibition of 14alpha demethylase, an enzyme involved in sterol synthesis, resulting in lysis of the fungal cell wall and fungal cell death. (NCIO4) [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Related Flora

Flora	Rank	Flora Definition	Family	Family Definition
Lysis	genus	[no description available]	Primulaceae	A plant family of the order ERICALES, class MAGNOLIOPSIDA, with flowers having both stamens and pistil, producing encapsulated fruits.[MeSH]

ID Source	ID
PubMed CID	467825
CHEMBL ID	294029
CHEBI ID	143825
SCHEMBL ID	939026
MeSH ID	M0271925

Synonym
D02556
ravuconazole (prop.inn)
benzonitrile, 4-[2-[(1r,2r)-2-(2,4-difluro-phenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]-
bms-207147
4-[2-[(1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1,2,4-triazol-1-yl)propyl]thiazol-4-yl]benzonitrile
bms-207,147
ravuconazole
er-30346
182760-06-1
er 30346
CHEMBL294029
4-[2-[(1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]benzonitrile
bms-20714
ravuconazolum
4-[2-[(2r,3r)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile
ravuconazol
CHEBI:143825
bms 207147
unii-95yh599jwv
p-(2-((alphar,betar)-2,4-difluoro-beta-hydroxy-alpha-methyl-beta-(1h-1,2,4-triazol-1-ylmethyl)phenethyl)-4-thiazolyl)benzonitrile
ravuconazole [inn]
benzonitrile, 4-(2-((1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl)-4-thiazolyl)-
95yh599jwv ,
3-(4-(4-cyanophenyl)thiazol-2-yl)-2-(2,4-difluorophenyl)-1-(1h-1,2,4-triazol-1-yl)-2-butanol
BCP9000424
AKOS015962202
benzonitrile, 4-[2-[(1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]-
benzonitrile, 4-[2-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]-, [r-(r,r)]-
ravuconazole [who-dd]
ravuconazole [mi]
ravuconazole [mart.]
(2r,3r)-3-[4-(4-cyanophenyl)thiazol-2-yl]-1-(1h-1,2,4-triazol-1-yl)-2-(2,4-difluorophenyl)-butan-2-ol
(2r,3r)-3-[4-(4-cyanophenyl)thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol
OPAHEYNNJWPQPX-RCDICMHDSA-N
(1r,2r)-4-[2-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-[1,2,4]triazol-1-yl-propyl]thiazol-4-yl]benzonitrile
SCHEMBL939026
bdbm50011476
DTXSID40171329
194798-96-4
mfcd00941002
HY-14272
4-(2-((2r,3r)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1h-1,2,4-triazol-1-yl)butan-2-yl)thiazol-4-yl)benzonitrile
CS-6927
DB06440
bms-207147/ravuconazole
bms 207147;er 30346;bms207147;er30346;bms-207147;er-30346
BCP05803
Q7296826
EX-A3369
bms-207147;er-30346
4-(2-((2r,3r)-rel-3-(2,4-difluorophenyl)-3-hydroxy-4-(1h-1,2,4-triazol-1-yl)butan-2-yl)thiazol-4-yl)benzonitrile
A855884
MS-27838

Excerpt	Reference	Relevance
"Ravuconazole (RVZ) is a new available human azole drug in Japan since 2018 and broad-spectrum antifungal agent."	( In vitro algaecid effect of itraconazole and ravuconazole on Prototheca species. Ito, T; Kamata, H; Kano, R; Miura, A; Suzuki, K, 2020)	1.54
"Ravuconazole (RVCZ) is a new human anti-fungal azole drug available in Japan since 2018 and is a broad-spectrum agent that exhibits excellent activity against dermatophytes. "	( In Vitro Ravuconazole Susceptibility of Anthropophilic Dermatophyte Strains Isolated from Japanese Patients. Harada, K; Hase, M; Hiruma, J; Hiruma, M; Kamata, H; Kano, R; Noguchi, H; Yokota, M, 2020)	2.42
"Ravuconazole (RVCZ) is a newly available human azole drug in Japan since 2018 and is a broad-spectrum antifungal agent that exhibits excellent activity against Candida albicans and Cryptococcus neoformans (formerly: Cryptococcus grubii). "	( Antifungal Susceptibility of Clinical Isolates and Artificially Produced Multi-azole-resistant Strains of Cryptococcus neoformans (formerly: Cryptococcus grubii) to Ravuconazole. Kamata, H; Kano, R; Sugita, T, 2020)	2.2
"Ravuconazole is an extended-spectrum triazole agent that is efficient in vitro against Candida spp. "	( In Vitro activity of ravuconazole against Candida auris and vaginal candida isolates. Dong, J; Kan, S; Liang, G; Liu, W; Song, N; Zhang, M; Zheng, H, 2021)	2.38
"Ravuconazole (RAV) is a triazole antifungal with broad spectrum and a novel alternative in the treatment of systemic fungal infections. "	( Development of a stability-indicating assay method by HPLC-DAD and MS characterization of forced degradation products of ravuconazole. Brêtas, CM; César, IC; Gazzinelli, BP, 2022)	2.37
"Ravuconazole is a fourth generation azole exerting strong antifungal activity, with low drug-drug interaction and hepatic dysfunction risks. "	( [Drug properties of fosravuconazole L-lysine ethanolate (NAILIN Aoki, Y; Nakano, M; Yamaguchi, H, )	1.88
"Ravuconazole (RVZ) is an antifungal azole compound and the active metabolite of fosravuconazole, which was approved for use in humans in Japan in 2018."	( High multi-azole-resistant Malassezia pachydermatis clinical isolates from canine Malassezia dermatitis. Aramaki, C; Kamata, H; Kano, R; Mori, Y; Murayama, N; Yamagishi, K; Yokoi, S, 2020)	1.28
"Ravuconazole is an experimental triazole derivative with potent and broad-spectrum antifungal activity and a remarkably long half-life in humans. "	( In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Lira, R; Payares, G; Romanha, AJ; Sanoja, C; Urbina, JA, 2003)	2.04
"Ravuconazole is a new antifungal triazole with broad-spectrum activity and a long half-life in plasma. "	( Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Armstrong, D; Avila, NA; Bacher, J; Groll, AH; Hemmings, M; Lyman, CA; Mickiene, D; Peter, J; Petraitiene, R; Petraitis, V; Roussillon, K; Walsh, TJ, 2004)	1.98
"Ravuconazole is a broad-spectrum antifungal triazole in clinical development. "	( Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits. Bacher, J; Groll, AH; Kelaher, A; Mickiene, D; Petraitiene, R; Petraitis, V; Sarafandi, A; Walsh, TJ; Wuerthwein, G, 2005)	2
"Ravuconazole (BMS-207147) is a long-lasting triazole antifungal agent active against a broad spectrum of fungal pathogens including non-albicans Candida, Aspergillus, Cryptococcus and key dermatophytic fungi."	( Effect of ravuconazole, a new triazole antifungal, in a rat intraabdominal abscess model. Hayasaki, Y; Mikamo, H; Satoh, M; Tamaya, T; Yin, XH, )	1.98

Excerpt	Reference	Relevance
"Ravuconazole has a broader antifungal spectrum than fluconazole and itraconazole, particularly against strains of Candida krusei and Cryptococcus neoformans [271854], [342757], [370312]."	( Ravuconazole Eisai/Bristol-Myers Squibb. Arikan, S; Rex, JH, 2002)	2.48
"Ravuconazole has shown efficacy in candidiasis in immunocompromised patients, and onychomycosis in healthy patients."	( New antifungal agents. Gupta, AK; Tomas, E, 2003)	1.04
"Ravuconazole has good efficacy and the potential to cure mucosal candidosis in the absence of a functional immune response."	( Efficacy of ravuconazole in treatment of mucosal candidosis in SCID mice. Clemons, KV; Stevens, DA, 2001)	1.41
"Ravuconazole has a broader antifungal spectrum than fluconazole and itraconazole, particularly against strains of Candida krusei and Cryptococcus neoformans [271854], [342757], [370312]."	( Ravuconazole Eisai/Bristol-Myers Squibb. Arikan, S; Rex, JH, 2002)	2.48

Excerpt	Reference	Relevance
"All ravuconazole-treated dogs consistently had negative serological test results during and until 30 days after treatment, regardless of the therapeutic scheme used."	( Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Bahia, MT; Caldas, IS; Carneiro, CM; Crepalde, G; de Lana, M; Diniz, Lde F; Guedes, PM; Talvani, A; Urbina, JA, 2010)	1.23
"Treatments of ravuconazole 5, 10 and 25 mg/kg po od were compared with itraconazole 2.5 and 5.0 mg/kg po bd and amphotericin B 1.25 mg/kg ip od."	( Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. Coco, BJ; Kirkpatrick, WR; Patterson, TF; Perea, S, 2002)	1.04

Excerpt	Reference	Relevance
" Drug-related adverse events were infrequent in all treatment arms."	( A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. Conetta, B; Gupta, AK; Leonardi, C; Pierce, PF; Stoltz, RR, 2005)	0.53
" Regarding safety, adverse events were observed in 83."	( Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study. Okubo, A; Tsubouchi, I; Watanabe, S, 2018)	0.78

Excerpt	Reference	Relevance
"In vivo studies have characterized the pharmacodynamic characteristics of the triazole fluconazole."	( In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Andes, D; Conklin, R; Marchillo, K; Stamstad, T, 2003)	0.58
"Ravuconazole is a new antifungal triazole with broad-spectrum activity and a long half-life in plasma."	( Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Armstrong, D; Avila, NA; Bacher, J; Groll, AH; Hemmings, M; Lyman, CA; Mickiene, D; Peter, J; Petraitiene, R; Petraitis, V; Roussillon, K; Walsh, TJ, 2004)	1.98
" Plasma concentration data were fitted to a three-compartment pharmacokinetic model."	( Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits. Bacher, J; Groll, AH; Kelaher, A; Mickiene, D; Petraitiene, R; Petraitis, V; Sarafandi, A; Walsh, TJ; Wuerthwein, G, 2005)	0.55
"The pharmacokinetics of ravuconazole fitted best to a three-compartment pharmacokinetic model."	( Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits. Bacher, J; Groll, AH; Kelaher, A; Mickiene, D; Petraitiene, R; Petraitis, V; Sarafandi, A; Walsh, TJ; Wuerthwein, G, 2005)	0.86

Excerpt	Reference	Relevance
" The clinical drug-drug interaction (DDI) potential of BFE1224 with cytochrome P450 (CYP) and transporter was assessed by using two types of cocktails in healthy subjects in separate clinical studies."	( Clinical Drug-Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects. Ishii, Y; Ito, Y; Matsuki, S; Ogawa, O; Sanpei, K; Schuck, EL; Takeda, K; Uemura, N, 2018)	0.71

Excerpt	Reference	Relevance
" Reduced toxicity, enhancement of bioavailability and counteraction of resistance are features desired by clinicians."	( Newer antifungal agents. Türel, O, 2011)	0.37
" amazonensis; ravuconazole is a second-generation triazole antifungal drug that has good bioavailability after oral administration and a long terminal half-life in humans, a broad activity spectrum, high effectiveness in treatment of mycosis and negligible side effects."	( In vitro antileishmanial activity of ravuconazole, a triazole antifungal drug, as a potential treatment for leishmaniasis. Cola Fernandes Rodrigues, J; de Souza, W; Lima Prado Godinho, J; Teixeira de Macedo Silva, S; Urbina, JA; Visbal, G, 2018)	1.11

Excerpt	Relevance	Reference
" Oral therapy with ravuconazole at a dosage of 30 mg/kg of body weight per day or the echinocandin LY-303366, given intravenously in a dosage of 5 or 10 mg/kg, was begun 24 h after a lethal or sublethal challenge, and results were compared with those for amphotericin B therapy and untreated controls."	( Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Andriole, VT; Marino, S; Roberts, J; Schock, K, 2000)	0.88
" Treatment efficacies with the five dosing intervals studied were similar, supporting the argument for the AUC/MIC ratio as the PK/PD parameter predictive of efficacy."	( In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Andes, D; Conklin, R; Marchillo, K; Stamstad, T, 2003)	0.58
" Ravuconazole showed linear plasma pharmacokinetics and a large volume of distribution while maintaining concentrations in plasma above the MIC throughout the dosing interval."	( Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Armstrong, D; Avila, NA; Bacher, J; Groll, AH; Hemmings, M; Lyman, CA; Mickiene, D; Peter, J; Petraitiene, R; Petraitis, V; Roussillon, K; Walsh, TJ, 2004)	1.45
" Four 12-week dosing regimens were used: 200 mg/day; 100 mg/week; 400 mg/week and placebo."	( A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. Conetta, B; Gupta, AK; Leonardi, C; Pierce, PF; Stoltz, RR, 2005)	0.53
"Following single dosing, ravuconazole demonstrated linear plasma pharmacokinetics across the investigated dosage range."	( Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits. Bacher, J; Groll, AH; Kelaher, A; Mickiene, D; Petraitiene, R; Petraitis, V; Sarafandi, A; Walsh, TJ; Wuerthwein, G, 2005)	0.86

Role	Description
ergosterol biosynthesis inhibitor	Any compound that inhibits one or more steps in the pathway leading to the synthesis of ergosterol.
antifungal drug	Any antifungal agent used to prevent or treat fungal infections in humans or animals.
EC 1.14.14.154 (sterol 14alpha-demethylase) inhibitor	Any EC 1.14.14.* (oxidoreductase acting on paired donors, incorporating of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitor that interferes with the action of sterol 14alpha-demethylase (EC 1.14.14.154).
antileishmanial agent	An antiprotozoal drug used to treat or prevent infections caused by protozoan parasites that belong to the genus Leishmania.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
triazoles	An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.
fluorobenzenes	Any fluoroarene that is a benzene or a substituted benzene carrying at least one fluoro group.
tertiary alcohol	A tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it.
1,3-thiazoles
nitrile	A compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cytochrome P450 3A4	Homo sapiens (human)	IC50 (µMol)	1.0100	0.0001	1.7536	10.0000	AID1872537
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	IC50 (µMol)	10.3700	0.0009	1.9014	10.0000	AID1138338
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by hormone	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion homeostasis	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cardiac muscle contraction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cellular response to xenobiotic stimulus	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane depolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion import across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
transcription cis-regulatory region binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ubiquitin protein ligase binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
identical protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein homodimerization activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
C3HC4-type RING finger domain binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (248)

Assay ID	Title	Year	Journal	Article
AID322861	Antifungal activity against azole-resistant Aspergillus fumigatus V41/26-CM3820 isolate from patient with pulmonary fibrosis by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID542418	Antimicrobial activity against Aspergillus terreus environmental isolate after 48 hrs by EUCAST test	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing.
AID307395	Antifungal activity against Candida krusei ATCC 6528 by broth microdilution assay	2007	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12	Discovery of novel indazole-linked triazoles as antifungal agents.
AID519445	Antimicrobial activity against Neosartorya pseudofischeri isolate CNM-CM-2270 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID519440	Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-3305 obtained from skin of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID666954	Antibacterial activity Bacillus subtilis NCIM 2250 after 24 hrs by NCCLS method	2012	European journal of medicinal chemistry, Aug, Volume: 54	Hybrids of ravuconazole: synthesis and biological evaluation.
AID549328	Antifungal activity against Apophysomyces spp. after 24 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID519439	Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-3303 obtained from skin of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID519423	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3134 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID520618	Antifungal activity against Candida parapsilosis by microdilution AFST-EUCAST method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain.
AID549319	Antifungal activity against Rhizopus microsporus after 48 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID529668	Antimicrobial activity against Paecilomyces lilacinus by microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Susceptibility testing and molecular classification of Paecilomyces spp.
AID532041	Antifungal activity against Lichtheimia ramosa clinical isolate after 24 hrs by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID575205	Antifungal activity against Cunninghamella echinulata UTHSC 03-3725 after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID563406	Antifungal activity against Aspergillus tubingensis isolate CM-4005 after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID575206	Antifungal activity against Cunninghamella echinulata FMR 10974 after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID547505	Half life in po dosed human	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID563391	Antifungal activity against Aspergillus tubingensis isolate CM-3585 after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID178950	Effective dose required to inhibit the systemic Aspergillosis fumigatus infection was determined in rat by peroral administration	2002	Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19	Synthesis of novel water soluble benzylazolium prodrugs of lipophilic azole antifungals.
AID322856	Antifungal activity against azole-resistant Aspergillus fumigatus V28/78-CM3275 isolate from patient with acute myeloid leukemia by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID519549	Antimicrobial activity against Aspergillus fumisynnematus isolate CNM-CM-2280 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID549325	Antifungal activity against Cunninghamella spp. after 48 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID432802	Antifungal activity against Sporothrix mexicana after 72 hrs by microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro antifungal susceptibilities of five species of sporothrix.
AID666953	Antibacterial activity Escherichia coli NCIM 2109 after 24 hrs by NCCLS method	2012	European journal of medicinal chemistry, Aug, Volume: 54	Hybrids of ravuconazole: synthesis and biological evaluation.
AID547504	Half life in mongrel dog	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID322864	Antifungal activity against azole-resistant Aspergillus fumigatus V49/09-CM4023 isolate from patient with chronic obstructive pulmonary disease by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID519433	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4420 obtained from nail of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID542417	Antimicrobial activity against Aspergillus terreus clinical isolate after 48 hrs by EUCAST test	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing.
AID547265	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Y assessed as production of antibody IgG at 12 mg/kg, po BID for 90 days measured up to 30 days by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID547513	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as reduction in IL10 production in right atrium at 12 mg/kg, po BID after 180 days by semiquantitative RT-PCR	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID547501	Antitrypanosomal activity against Trypanosoma cruzi Y infected in mongrel dog assessed as reduction in parasite-induced intrafascicular collagen deposition at 7 mg/kg, po BID after 180 days by semiquantitative RT-PCR	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1138341	Aqueous solubility of the compound in phosphate buffer at pH 7.4	2014	Journal of medicinal chemistry, May-08, Volume: 57, Issue:9	Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID563418	Antifungal activity against Aspergillus tubingensis isolate CM-4897 obtained from blood culture after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID432799	Antifungal activity against Sporothrix brasiliensis after 72 hrs by microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro antifungal susceptibilities of five species of sporothrix.
AID529667	Antimicrobial activity against Paecilomyces variotii by microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Susceptibility testing and molecular classification of Paecilomyces spp.
AID563410	Antifungal activity against Aspergillus tubingensis isolate CM-3177 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID432801	Antifungal activity against Sporothrix globosa after 72 hrs by microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro antifungal susceptibilities of five species of sporothrix.
AID432800	Antifungal activity against Sporothrix schenckii after 72 hrs by microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro antifungal susceptibilities of five species of sporothrix.
AID563392	Antifungal activity against Aspergillus niger isolate CM-3586 obtained from catheter of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID547258	Antimicrobial activity against Trypanosoma cruzi Berenice-78 infected in mongrel dog assessed as survival of dog at 7 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID549313	Antifungal activity against Mucor circinelloides after 48 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID1600166	Antibacterial activity against Escherichia coli NCIM 2574 assessed as zone of inhibition at 80 ug/well incubated for 24 to 48 hrs by by agar well diffusion method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis of new thiazolyl-pyrazolyl-1,2,3-triazole derivatives as potential antimicrobial agents.
AID547263	Antimicrobial activity against Trypanosoma cruzi Y infected in mongrel dog assessed as parasite level in blood of dog at 7 mg/kg, po BID started 12 to 22 days postinfection measured after 30 days by PCR analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID118896	In vivo antifungal activity against murine candidosis model after peroral administration with 1 mg/kg for 5 days.(percent protection for 100% mortality with fluconazole-treated group.)	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol.
AID178948	Effective dose required to inhibit the pulmonary Aspergillosis fumigatus infection was determined in rat by peroral administration	2002	Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19	Synthesis of novel water soluble benzylazolium prodrugs of lipophilic azole antifungals.
AID73614	In vitro antifungal activity against 6 filamentous fungi	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID73613	The compound was tested in vitro for antifungal activity against 6 filamentous fungi.	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol.
AID547250	Toxicity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as weight loss at 7 mg/kg, po BID for 90 days started 12 to 22 days postinfection measured after 6 months	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID531471	Antimicrobial activity against azole-resistant Aspergillus fumigatus harboring Tandem repeat-L98H (TR) mutation in cyp51A gene after 48 hrs by microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus.
AID549314	Antifungal activity against Mycocladus corymbifer after 24 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID307394	Antifungal activity against Candida glabrata ATCC 34138 by broth microdilution assay	2007	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12	Discovery of novel indazole-linked triazoles as antifungal agents.
AID547502	Antitrypanosomal activity against Trypanosoma cruzi Berenice-78 infected in mongrel dog assessed as reduction in parasite-induced intrafascicular collagen deposition in right atrium at 12 mg/kg, po BID after 180 days by semiquantitative RT-PCR	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID549311	Antifungal activity against Rhizopus oryzae after 48 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID563405	Antifungal activity against Aspergillus tubingensis isolate CM-4003 after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID322857	Antifungal activity against azole-resistant Aspergillus fumigatus V34/75-CM3276 isolate from patient with hyper-immunoglobulin E syndrome by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID666949	Antibacterial activity Pseudomonas aeruginosa NCIM 2036 at 100 ug/disc by agar-well diffusion assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Hybrids of ravuconazole: synthesis and biological evaluation.
AID563413	Antifungal activity against Aspergillus tubingensis isolate CM-4000 after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID520620	Antifungal activity against Candida metapsilosis by microdilution AFST-EUCAST method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain.
AID666950	Antifungal activity Aspergillus niger NCIM 545 at 100 ug/disc by agar-well diffusion assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Hybrids of ravuconazole: synthesis and biological evaluation.
AID547281	Antitrypanosomal activity against Trypanosoma cruzi Y infected in mongrel dog assessed as reduction in parasite-induced intrafascicular collagen deposition in right atrium at 12 mg/kg, po BID after 180 days by semiquantitative RT-PCR	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID547503	Antitrypanosomal activity against Trypanosoma cruzi Berenice-78 infected in mongrel dog assessed as reduction in parasite-induced intrafascicular collagen deposition in right atrium at 7 mg/kg, po BID after 180 days by semiquantitative RT-PCR	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID563420	Antifungal activity against Aspergillus foetidus isolate CM-4995 obtained from prosthesis after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID307403	Antifungal activity against Aspergillus niger ATCC 9042 by broth microdilution assay	2007	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12	Discovery of novel indazole-linked triazoles as antifungal agents.
AID1138332	Antimicrobial activity against Aspergillus fumigatus 7544 after 48 hrs by serial dilution method	2014	Journal of medicinal chemistry, May-08, Volume: 57, Issue:9	Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID547257	Antimicrobial activity against Trypanosoma cruzi Y infected in mongrel dog assessed as survival of dog at 7 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID575208	Antifungal activity against Cunninghamella echinulata UTHSC 01-2298 after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID547248	Toxicity in mongrel dog infected with Trypanosoma cruzi Y assessed as weight loss at 7 mg/kg, po BID for 90 days started 12 to 22 days postinfection measured after 6 months	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID432803	Antifungal activity against Sporothrix albicans after 72 hrs by microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro antifungal susceptibilities of five species of sporothrix.
AID559691	Antimicrobial activity against Rhizopus oryzae after 24 hrs by broth microdilution checkerboard procedure	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.
AID118898	In vivo antifungal activity against murine candidosis model after peroral administration with 1 mg/kg for 5 days.(percent protection for 100% mortality with untreated group)	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol.
AID322855	Antifungal activity against azole-resistant Aspergillus fumigatus V27/28-CM3273 isolate from patient by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID549315	Antifungal activity against Mycocladus corymbifer after 48 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID1138328	Antimicrobial activity against Candida albicans Y0109 after 24 hrs by serial dilution method	2014	Journal of medicinal chemistry, May-08, Volume: 57, Issue:9	Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID549322	Antifungal activity against Rhizomucor variabilis after 24 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID520619	Antifungal activity against Candida orthopsilosis by microdilution AFST-EUCAST method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain.
AID575201	Antifungal activity against Cunninghamella bertholletiae FMR-9598 after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID519425	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3537 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID519441	Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-3764 obtained from oropharyngeal exudate of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID1600165	Antifungal activity against Rhodotorula glutinis NCIM 3168 assessed as zone of inhibition at 80 ug/well incubated for 48 to 72 hrs by by agar well diffusion method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis of new thiazolyl-pyrazolyl-1,2,3-triazole derivatives as potential antimicrobial agents.
AID547243	Toxicity in mongrel dog infected with Trypanosoma cruzi Y assessed as weight loss at 12 mg/kg, po BID for 90 days started 12 to 22 days postinfection measured after 1 day	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID307397	Antifungal activity against Candida lusitaniae ATCC 42720 by broth microdilution assay	2007	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12	Discovery of novel indazole-linked triazoles as antifungal agents.
AID575207	Antifungal activity against Cunninghamella echinulata FMR 10973 after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID1600168	Antibacterial activity against Staphylococcus albus NCIM 2178 assessed as zone of inhibition at 80 ug/well incubated for 24 to 48 hrs by by agar well diffusion method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis of new thiazolyl-pyrazolyl-1,2,3-triazole derivatives as potential antimicrobial agents.
AID1456578	Antifungal activity against Candida parapsilosis isolate 22019 by micro-broth dilution method	2017	Bioorganic & medicinal chemistry letters, 05-15, Volume: 27, Issue:10	Design, synthesis, and in vitro evaluation of novel antifungal triazoles.
AID549312	Antifungal activity against Mucor circinelloides after 24 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID547506	Cmax in Beagle dog at 10 mg/kg	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1456577	Antifungal activity against Candida albicans isolate SC5314 by micro-broth dilution method	2017	Bioorganic & medicinal chemistry letters, 05-15, Volume: 27, Issue:10	Design, synthesis, and in vitro evaluation of novel antifungal triazoles.
AID547266	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Y assessed as production of antibody IgG2 at 12 mg/kg, po BID for 90 days measured up to 30 days by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1138327	Antimicrobial activity against Candida albicans SC5314 after 24 hrs by serial dilution method	2014	Journal of medicinal chemistry, May-08, Volume: 57, Issue:9	Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID547262	Antimicrobial activity against Trypanosoma cruzi Berenice-78 infected in mongrel dog assessed as parasite level in blood of dog at 12 mg/kg, po BID started 12 to 22 days postinfection measured after 6 months by PCR analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID519431	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4387 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID531468	Antimicrobial activity against azole-susceptible Aspergillus fumigatus after 48 hrs by microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus.
AID547244	Toxicity in mongrel dog infected with Trypanosoma cruzi Y assessed as weight loss at 7 mg/kg, po BID for 90 days started 12 to 22 days postinfection measured after 1 day	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID563416	Antifungal activity against Aspergillus niger isolate CM-4262 after 48 hrs by EUCAST broth dilution method Ophthalmic	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID519443	Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-4328 obtained from cornea of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID519432	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4415 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID666952	Antibacterial activity Staphylococcus aureus NCIM 2079 after 24 hrs by NCCLS method	2012	European journal of medicinal chemistry, Aug, Volume: 54	Hybrids of ravuconazole: synthesis and biological evaluation.
AID563394	Antifungal activity against Aspergillus niger isolate CM-3641 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID563409	Antifungal activity against Aspergillus tubingensis isolate CM-3125 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID549317	Antifungal activity against Cunninghamella bertholletiae after 48 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID1138340	Aqueous solubility of the compound in hydrochloric acid solution at pH 1.2	2014	Journal of medicinal chemistry, May-08, Volume: 57, Issue:9	Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID1138330	Antimicrobial activity against Cryptococcus neoformans 32609 after 72 hrs by serial dilution method	2014	Journal of medicinal chemistry, May-08, Volume: 57, Issue:9	Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID519429	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4330 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID547268	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Y assessed as production of antibody IgG2 at 7 mg/kg, po BID for 90 days measured up to 30 days by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID532043	Antifungal activity against Lichtheimia corymbifera clinical isolate after 24 hrs by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID547259	Antimicrobial activity against Trypanosoma cruzi Y infected in mongrel dog assessed as parasite level in blood of dog at 12 mg/kg, po BID started 12 to 22 days postinfection measured after 30 days by PCR analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID322858	Antifungal activity against azole-resistant Aspergillus fumigatus V34/76-CM3277 isolate from patient with hyper-immunoglobulin E syndrome by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID666955	Antibacterial activity Pseudomonas aeruginosa NCIM 2036 after 24 hrs by NCCLS method	2012	European journal of medicinal chemistry, Aug, Volume: 54	Hybrids of ravuconazole: synthesis and biological evaluation.
AID563398	Antifungal activity against Aspergillus tubingensis isolate CM-4264 obtained from blood culture after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID322862	Antifungal activity against azole-resistant Aspergillus fumigatus V45/07-CM3819 isolate from patient with chronic granulomatous disease by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID519446	Antimicrobial activity against Neosartorya pseudofischeri isolate CNM-CM-4060 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID220226	In vitro for antifungal activity against 10 yeasts	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID519430	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4370 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID563412	Antifungal activity against Aspergillus tubingensis isolate CM-3654 obtained from blood culture after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID322863	Antifungal activity against azole-resistant Aspergillus fumigatus V48/27-CM3936 isolate from patient with acute myeloid leukemia by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID563404	Antifungal activity against Aspergillus tubingensis isolate CM-3810 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID547512	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as reduction in INFgamma production in right atrium at 12 mg/kg, po BID after 180 days by semiquantitative RT-PCR	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID531470	Antimicrobial activity against azole-resistant Aspergillus fumigatus harboring M220V, M220K, M220T and M220I mutation in cyp51A gene after 48 hrs by microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus.
AID1872523	Water solubility of the compound at pH 7.4	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID7989	Conversion rate of the prodrug in human plasma; ND means no data	2002	Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19	Synthesis of novel water soluble benzylazolium prodrugs of lipophilic azole antifungals.
AID549318	Antifungal activity against Rhizopus microsporus after 24 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID519449	Antimicrobial activity against Aspergillus viridinutans isolate CNM-CM-4518 obtained from nail of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID563402	Antifungal activity against Aspergillus niger isolate CM-5095 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID549329	Antifungal activity against Apophysomyces spp. after 48 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID1872533	Antifungal activity against Microsporum gypseum	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID547272	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as production of antibody IgG2 at 7 mg/kg, po BID for 90 days measured up to 30 days by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID547515	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as reduction in IL10 production in right atrium at 7 mg/kg, po BID after 180 days by semiquantitative RT-PCR	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID549310	Antifungal activity against Rhizopus oryzae after 24 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID519450	Antimicrobial activity against Aspergillus fumigatus ATCC 2004305 after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID547507	Half life in mouse	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID547251	Antimicrobial activity against Trypanosoma cruzi Y infected in mongrel dog assessed as suppression of microbial proliferation at 12 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID307398	Antifungal activity against Candida tropicalis ATCC 750 by broth microdilution assay	2007	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12	Discovery of novel indazole-linked triazoles as antifungal agents.
AID563390	Antifungal activity against Aspergillus tubingensis isolate CM-3507 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID563414	Antifungal activity against Aspergillus tubingensis isolate CM-4001 after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID547255	Antimicrobial activity against Trypanosoma cruzi Y infected in mongrel dog assessed as survival of dog at 12 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID519438	Antimicrobial activity against Aspergillus fumisynnematus isolate CNM-CM-3227 obtained from bronchoalveolar lavage fluid of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID563387	Antifungal activity against Aspergillus niger isolate CM-3236 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID547247	Toxicity in mongrel dog infected with Trypanosoma cruzi Y assessed as weight loss at 12 mg/kg, po BID for 90 days started 12 to 22 days postinfection measured after 6 months	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID519436	Antimicrobial activity against Aspergillus fumisynnematus isolate CNM-CM-4063 obtained from bronchoalveolar aspirate of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID563396	Antifungal activity against Aspergillus niger isolate CM-4004 obtained from after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID563401	Antifungal activity against Aspergillus tubingensis isolate CM-5094 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID549327	Antifungal activity against Actinomucor spp. after 48 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID549326	Antifungal activity against Actinomucor spp. after 24 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID563417	Antifungal activity against Aspergillus tubingensis isolate CM-4352 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID322859	Antifungal activity against azole-resistant Aspergillus fumigatus V34/77-CM3278 isolate from patient with hyper-immunoglobulin E syndrome by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID525142	Antifungal activity against Fusarium thapsinum by microdilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
AID1456579	Antifungal activity against Cryptococcus neoformans isolate 32605 by micro-broth dilution method	2017	Bioorganic & medicinal chemistry letters, 05-15, Volume: 27, Issue:10	Design, synthesis, and in vitro evaluation of novel antifungal triazoles.
AID525139	Antifungal activity against Fusarium moniliforme clade 1 by microdilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
AID1138331	Antimicrobial activity against Candida glabrata 537 after 24 hrs by serial dilution method	2014	Journal of medicinal chemistry, May-08, Volume: 57, Issue:9	Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID575204	Antifungal activity against Cunninghamella bertholletiae UTHSC 06-1945 after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID322854	Antifungal activity against azole-resistant Aspergillus fumigatus V13/03-CM3272 isolate from patient with X-linked chronic granulomatous disease by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID519448	Antimicrobial activity against Aspergillus viridinutans isolate CNM-CM-3147 obtained from oropharyngeal exudate of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID118760	In vivo antifungal activity against murine candidosis model after peroral administration with 0.5 mg/kg at various time intervals. (percent protection for 100% mortality with fluconazole-treated group.)	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol.
AID666956	Antifungal activity Aspergillus niger NCIM 545 after 24 to 72 hrs by NCCLS method	2012	European journal of medicinal chemistry, Aug, Volume: 54	Hybrids of ravuconazole: synthesis and biological evaluation.
AID118765	In vivo antifungal activity against murine candidosis model after peroral administration with 0.5 mg/kg at various time intervals. (percent protection for 100% mortality with untreated group)	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol.
AID563407	Antifungal activity against Aspergillus tubingensis isolate CM-4688 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID547242	Half life in human	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID532045	Antifungal activity against Lichtheimia ornata clinical isolate after 24 hrs by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID547256	Antimicrobial activity against Trypanosoma cruzi Berenice-78 infected in mongrel dog assessed as survival of dog at 12 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID322852	Antifungal activity against azole-resistant Aspergillus fumigatus M03/669-CM2627 isolate from patient by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID119038	Tested in vivo for anti-candida activity in mice model 1 (dose:0.5 mg/kg, fluconazole-treated group)	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID1872537	Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone as substrate by LC-MS/MS analysis	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID322860	Antifungal activity against azole-resistant Aspergillus fumigatus V34/78-CM3279 isolate from patient with hyper-immunoglobulin E syndrome by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID1600169	Antifungal activity against Aspergillus niger NCIM 504 assessed as zone of inhibition at 80 ug/well incubated for 48 to 72 hrs by by agar well diffusion method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis of new thiazolyl-pyrazolyl-1,2,3-triazole derivatives as potential antimicrobial agents.
AID666951	Antifungal activity Candida albicans NCIM 3471 at 100 ug/disc by agar-well diffusion assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Hybrids of ravuconazole: synthesis and biological evaluation.
AID563403	Antifungal activity against Aspergillus tubingensis isolate CM-3123 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID519424	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3364 obtained from bronchoalveolar lavage fluid of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID666946	Antibacterial activity Staphylococcus aureus NCIM 2079 at 100 ug/disc by agar-well diffusion assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Hybrids of ravuconazole: synthesis and biological evaluation.
AID563388	Antifungal activity against Aspergillus niger isolate CM-3257 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID549316	Antifungal activity against Cunninghamella bertholletiae after 24 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID575202	Antifungal activity against Cunninghamella bertholletiae UTHSC 04-2581 after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID519428	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3599 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID519442	Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-3740 obtained from oropharyngeal exudate of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID519447	Antimicrobial activity against Neosartorya pseudofischeri isolate CNM-CM-3914 obtained from nail of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID563393	Antifungal activity against Aspergillus niger isolate CM-3636 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID519422	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-1290 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID519444	Antimicrobial activity against Neosartorya pseudofischeri isolate CNM-CM-3769 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID525141	Antifungal activity against Fusarium moniliforme clade 3 by microdilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
AID532044	Antifungal activity against Lichtheimia corymbifera clinical isolate after 48 hrs by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID307402	Antifungal activity against Aspergillus terreus ATCC 28301by broth microdilution assay	2007	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12	Discovery of novel indazole-linked triazoles as antifungal agents.
AID666957	Antifungal activity Candida albicans NCIM 3471 after 24 to 72 hrs by NCCLS method	2012	European journal of medicinal chemistry, Aug, Volume: 54	Hybrids of ravuconazole: synthesis and biological evaluation.
AID549321	Antifungal activity against Rhizomucor pusillus after 48 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID322865	Antifungal activity against azole-resistant Aspergillus fumigatus V49/77-CM4050 isolate from patient with acute myeloid leukemia by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID1456582	Antifungal activity against Trichophyton rubrum isolate cmccftla by micro-broth dilution method	2017	Bioorganic & medicinal chemistry letters, 05-15, Volume: 27, Issue:10	Design, synthesis, and in vitro evaluation of novel antifungal triazoles.
AID519435	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4428 obtained from skin of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID220225	The compound was tested in vitro for antifungal activity against 10 yeasts.	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol.
AID563397	Antifungal activity against Aspergillus niger isolate CM-4213 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID547252	Antimicrobial activity against Trypanosoma cruzi Berenice-78 infected in mongrel dog assessed as suppression of microbial proliferation at 12 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1456576	Antifungal activity against Candida albicans isolate Y0109 by micro-broth dilution method	2017	Bioorganic & medicinal chemistry letters, 05-15, Volume: 27, Issue:10	Design, synthesis, and in vitro evaluation of novel antifungal triazoles.
AID547271	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as production of antibody IgG at 7 mg/kg, po BID for 90 days measured up to 30 days by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID559695	Antimicrobial activity against Rhizomucor pusillus after 24 hrs by broth microdilution checkerboard procedure	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.
AID525140	Antifungal activity against Fusarium moniliforme clade 2 by microdilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
AID563411	Antifungal activity against Aspergillus niger isolate CM-3551 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID307396	Antifungal activity against Cryptococcus neoformans ATCC 21019 by broth microdilution assay	2007	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12	Discovery of novel indazole-linked triazoles as antifungal agents.
AID1600171	Antifungal activity against Candida albicans NCIM 3100 assessed as inhibition of fungal growth incubated for 48 to 72 hrs by broth microdilution susceptibility method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis of new thiazolyl-pyrazolyl-1,2,3-triazole derivatives as potential antimicrobial agents.
AID559692	Antimicrobial activity against Mycocladus corymbiferus after 24 hrs by broth microdilution checkerboard procedure	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.
AID119042	Tested in vivo for anti-candida activity in mice model 1 (dose: 0.5 mg/kg, untreated group).	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID549323	Antifungal activity against Rhizomucor variabilis after 48 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID559693	Antimicrobial activity against Mucor circinelloides after 24 hrs by broth microdilution checkerboard procedure	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.
AID307401	Antifungal activity against Aspergillus flavus ATCC MYA-1004 by broth microdilution assay	2007	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12	Discovery of novel indazole-linked triazoles as antifungal agents.
AID307399	Antifungal activity against Candida parapsilosis ATCC 21019 by broth microdilution assay	2007	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12	Discovery of novel indazole-linked triazoles as antifungal agents.
AID547261	Antimicrobial activity against Trypanosoma cruzi Y infected in mongrel dog assessed as parasite level in blood of dog at 12 mg/kg, po BID started 12 to 22 days postinfection measured after 6 months by PCR analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID547253	Antimicrobial activity against Trypanosoma cruzi Y infected in mongrel dog assessed as suppression of microbial proliferation at 7 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID547267	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Y assessed as production of antibody IgG at 7 mg/kg, po BID for 90 days measured up to 30 days by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1456583	Antifungal activity against Microsporum gypseum isolate cmccftla by micro-broth dilution method	2017	Bioorganic & medicinal chemistry letters, 05-15, Volume: 27, Issue:10	Design, synthesis, and in vitro evaluation of novel antifungal triazoles.
AID1138338	Inhibition of human ERG expressed in CHO cells by whole-cell patch clamp assay	2014	Journal of medicinal chemistry, May-08, Volume: 57, Issue:9	Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID1456581	Antifungal activity against Aspergillus fumigatus isolate 7544 by micro-broth dilution method	2017	Bioorganic & medicinal chemistry letters, 05-15, Volume: 27, Issue:10	Design, synthesis, and in vitro evaluation of novel antifungal triazoles.
AID563415	Antifungal activity against Aspergillus foetidus isolate CM-4002 after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID307393	Antifungal activity against Candida albicans ATCC 36082 by broth microdilution assay	2007	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12	Discovery of novel indazole-linked triazoles as antifungal agents.
AID21769	Solubility of the prodrug in water was determined	2002	Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19	Synthesis of novel water soluble benzylazolium prodrugs of lipophilic azole antifungals.
AID547264	Antimicrobial activity against Trypanosoma cruzi Berenice-78 infected in mongrel dog assessed as parasite level in blood of dog at 7 mg/kg, po BID started 12 to 22 days postinfection measured after 30 days by PCR analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID666948	Antibacterial activity Bacillus subtilis NCIM 2250 at 100 ug/disc by agar-well diffusion assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Hybrids of ravuconazole: synthesis and biological evaluation.
AID563400	Antifungal activity against Aspergillus niger isolate CM-4316 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID563419	Antifungal activity against Aspergillus tubingensis isolate CM-4899 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID1600170	Antibacterial activity against Proteus mirabilis NCIM 2388 assessed as zone of inhibition at 80 ug/well incubated for 24 to 48 hrs by by agar well diffusion method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis of new thiazolyl-pyrazolyl-1,2,3-triazole derivatives as potential antimicrobial agents.
AID563389	Antifungal activity against Aspergillus niger isolate CM-3506 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID549324	Antifungal activity against Cunninghamella spp. after 24 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID119045	The compound was tested in vivo for anti-candida activity in mice model 2(dose: 1 mg/kg, untreated group).	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID1138329	Antimicrobial activity against Candida parapsilosis 22019 after 24 hrs by serial dilution method	2014	Journal of medicinal chemistry, May-08, Volume: 57, Issue:9	Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID563408	Antifungal activity against Aspergillus foetidus isolate CM-5264 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID322853	Antifungal activity against azole-resistant Aspergillus fumigatus V13/02-CM3271 isolate from patient with X-linked chronic granulomatous disease by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID563399	Antifungal activity against Aspergillus tubingensis isolate CM-4296 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID563395	Antifungal activity against Aspergillus niger isolate CM-3672 obtained from cutaneous layer of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID1600173	Antifungal activity against Rhodotorula glutinis NCIM 3168 assessed as inhibition of fungal growth incubated for 48 to 72 hrs by broth microdilution susceptibility method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis of new thiazolyl-pyrazolyl-1,2,3-triazole derivatives as potential antimicrobial agents.
AID1456580	Antifungal activity against Candida glabrata isolate 537 by micro-broth dilution method	2017	Bioorganic & medicinal chemistry letters, 05-15, Volume: 27, Issue:10	Design, synthesis, and in vitro evaluation of novel antifungal triazoles.
AID547514	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as reduction in INFgamma production in right atrium at 7 mg/kg, po BID after 180 days by semiquantitative RT-PCR	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID20897	Aqueous solubility was determined	2003	Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21	Phosphonooxymethyl prodrugs of the broad spectrum antifungal azole, ravuconazole: synthesis and biological properties.
AID531469	Antimicrobial activity against azole-resistant Aspergillus fumigatus harboring G54V, G54E, G54R and G54W mutation in cyp51A gene after 48 hrs by microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus.
AID559694	Antimicrobial activity against Rhizopus microsporus after 24 hrs by broth microdilution checkerboard procedure	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.
AID1600167	Antifungal activity against Candida albicans NCIM 3100 assessed as zone of inhibition at 80 ug/well incubated for 48 to 72 hrs by by agar well diffusion method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis of new thiazolyl-pyrazolyl-1,2,3-triazole derivatives as potential antimicrobial agents.
AID547249	Toxicity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as weight loss at 12 mg/kg, po BID for 90 days started 12 to 22 days postinfection measured after 6 months	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1600172	Antifungal activity against Aspergillus niger NCIM 504 assessed as inhibition of fungal growth incubated for 48 to 72 hrs by broth microdilution susceptibility method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis of new thiazolyl-pyrazolyl-1,2,3-triazole derivatives as potential antimicrobial agents.
AID178952	Effective dose required to inhibit the systemic Candida albicans infection was determined in rat by peroral administration	2002	Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19	Synthesis of novel water soluble benzylazolium prodrugs of lipophilic azole antifungals.
AID307400	Antifungal activity against Aspergillus fumigatus ATCC 16424 by broth microdilution assay	2007	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12	Discovery of novel indazole-linked triazoles as antifungal agents.
AID549320	Antifungal activity against Rhizomucor pusillus after 24 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID547270	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as production of antibody IgG2 at 12 mg/kg, po BID for 90 days measured up to 30 days by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID547269	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as production of antibody IgG at 12 mg/kg, po BID for 90 days measured up to 30 days by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID532046	Antifungal activity against Lichtheimia ornata clinical isolate after 48 hrs by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID519426	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3538 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID547260	Antimicrobial activity against Trypanosoma cruzi Berenice-78 infected in mongrel dog assessed as parasite level in blood of dog at 12 mg/kg, po BID started 12 to 22 days postinfection measured after 30 days by PCR analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID519427	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3583 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID666947	Antibacterial activity Escherichia coli NCIM 2109 at 100 ug/disc by agar-well diffusion assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Hybrids of ravuconazole: synthesis and biological evaluation.
AID575200	Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID519434	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4426 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID532042	Antifungal activity against Lichtheimia ramosa clinical isolate after 48 hrs by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID547254	Antimicrobial activity against Trypanosoma cruzi Berenice-78 infected in mongrel dog assessed as suppression of microbial proliferation at 7 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID575203	Antifungal activity against Cunninghamella bertholletiae UTHSC 03-2241 after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID119047	The compound was tested in vivo for anti-candida activity in mice model 2(dose :1 mg/kg,fluconazole-treated group)	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	12 (9.92)	18.2507
2000's	61 (50.41)	29.6817
2010's	27 (22.31)	24.3611
2020's	21 (17.36)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	7 (5.60%)	5.53%
Reviews	15 (12.00%)	6.00%
Case Studies	4 (3.20%)	4.05%
Observational	0 (0.00%)	0.25%
Other	99 (79.20%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
amlodipine Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.	7.25	1	0	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent
anastrozole [no description available]	2.11	1	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
bicalutamide bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.	2.11	1	0	(trifluoromethyl)benzenes; monocarboxylic acid amide; monofluorobenzenes; nitrile; sulfone; tertiary alcohol
ciclopirox [no description available]	4.07	1	0	cyclic hydroxamic acid; hydroxypyridone antifungal drug; pyridone	antibacterial agent; antiseborrheic
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	2.07	1	0	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
cisapride Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed). cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.	2.1	1	0	benzamides
fenbendazole Fenbendazole: Antinematodal benzimidazole used in veterinary medicine.. fenbendazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted at positons 2 and 5 by (methoxycarbonyl)amino and phenylsulfanediyl groups, respectively. A broad-spectrum anthelmintic, it is used, particularly in veterinary medicine, for the treatment of nematodal infections.	2.41	1	0	aryl sulfide; benzimidazoles; carbamate ester	antinematodal drug
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	8.24	27	0	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
flucytosine Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.. flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.	5.42	7	0	aminopyrimidine; nucleoside analogue; organofluorine compound; pyrimidine antifungal drug; pyrimidone	prodrug
itraconazole [no description available]	5.34	17	0	piperazines
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	3.43	7	0	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
miconazole Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion.. 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group.. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.	3.11	1	0	dichlorobenzene; ether; imidazoles
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	7.02	1	0	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
galactose galactopyranose : The pyranose form of galactose.	2.02	1	0	D-galactose; galactopyranose	Escherichia coli metabolite; mouse metabolite
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	2.41	1	0	pyrrole; secondary amine
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	5.48	8	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
thiazoles [no description available]	14.41	100	7	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
azomycin azomycin: RN given refers to parent cpd with specified locant; structure	7.71	8	3	C-nitro compound; imidazoles	antitubercular agent
streptomycin [no description available]	2.21	1	0	antibiotic antifungal drug; antibiotic fungicide; streptomycins	antibacterial drug; antifungal agrochemical; antimicrobial agent; antimicrobial drug; bacterial metabolite; protein synthesis inhibitor
benzonidazole benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.	7.67	8	3	C-nitro compound; imidazoles; monocarboxylic acid amide	antiprotozoal drug
azides Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.	3.51	1	0	pseudohalide anion	mitochondrial respiratory-chain inhibitor
loceryl amorolfine: RN given refers to parent cpd. amorolfine : A member of the class of morpholines that is cis-2,6-dimethylmorpholine in which the hydrogen attached to the nitrogen is replaced by a racemic 2-methyl-3-[p-(2-methylbutan-2-yl)phenyl]propyl group. An inhibitor of the action of squalene monooxygenase, Delta(14) reductase and D7-D8 isomerase and an antifungal agent, it is used (generally as its hydrochloride salt) for the topical treatment of fungal nail and skin infections.	4.07	1	0	morpholine antifungal drug; tertiary amino compound	EC 1.14.13.132 (squalene monooxygenase) inhibitor; EC 1.3.1.70 (Delta(14)-sterol reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor
itraconazole Itraconazole: A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.. itraconazole : An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis.	8.12	30	0	aromatic ether; conazole antifungal drug; cyclic ketal; dichlorobenzene; dioxolane; N-arylpiperazine; triazole antifungal drug; triazoles	EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; Hedgehog signaling pathway inhibitor; P450 inhibitor
fadrozole Fadrozole: A selective aromatase inhibitor effective in the treatment of estrogen-dependent disease including breast cancer.	2.11	1	0	imidazopyridine
nelfinavir Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.. nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.	8.41	1	1	aryl sulfide; benzamides; organic heterobicyclic compound; phenols; secondary alcohol; tertiary amino compound	antineoplastic agent; HIV protease inhibitor
thiazolyl blue thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.	2.02	1	0	organic bromide salt	colorimetric reagent; dye
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	14.51	102	7	1,2,3-triazole
voriconazole Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.	9.19	42	0	conazole antifungal drug; difluorobenzene; pyrimidines; tertiary alcohol; triazole antifungal drug	P450 inhibitor
eberconazole eberconazole : A racemate comprising equimolar amounts of (R)- and (S)-eberconazole. Used (as its nitrate salt) for topical treatment of superficial mycoses.. 1-(2,4-dichloro-10,11-dihydrodibenzo[a,d][7]annulen-5-yl)imidazole : A member of the class of dibenzannulenes that is 10,11-dihydrodibenzo[a,d][7]annulene carrying two chloro substituents at positions 2 and 4 as well as an imidazol-1-yl substituent at position 5.	2.04	1	0	dibenzannulene; imidazoles; organochlorine compound
anidulafungin Anidulafungin: Echinocandin antifungal agent that is used in the treatment of CANDIDEMIA and CANDIDIASIS.. anidulafungin : A semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used for the treatment of invasive candidiasis.	5.14	8	0	antibiotic antifungal drug; azamacrocycle; echinocandin; heterodetic cyclic peptide; semisynthetic derivative
albaconazole albaconazole: UR-9825 is the (1R,2R)-isomer; structure in first source	10.92	13	0
tacrolimus Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.	2.05	1	0	macrolide lactam	bacterial metabolite; immunosuppressive agent
sm 8668 Sch 39304: Sch 42427 is the active entantiomer of the antifungal agent Sch 39304 which consists of Sch 42426 & Sch 42427; Sch 42426, the (S,S)-isomer, is inactive	2.4	2	0
ketoconazole (2R,4S)-ketoconazole : A cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine which dioxolane moiety has (2R,4S)-configuration.	3.51	1	0	cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
posaconazole [no description available]	9.09	38	0	aromatic ether; conazole antifungal drug; N-arylpiperazine; organofluorine compound; oxolanes; triazole antifungal drug; triazoles	trypanocidal drug
l 743,872 [no description available]	6.59	10	0
micafungin Micafungin: A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.. micafungin : A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy.	5	12	0	antibiotic antifungal drug; echinocandin	antiinfective agent
tak 187 TAK 187: structure in first source; ergosterol biosynthesis inhibitor with possible usage against Trypanosoma	2.4	2	0
efinaconazole efinaconazole: an antifungal agent; structure in first source. efinaconazole : A member of the class of triazoles that is butan-2-ol which is substituted at positions 1, 2, and 3 by 1,2,4-triazol-1-yl, 2,4-difluorophenyl, and 4-methylenepiperidin-1-yl groups, respectively (the 2R,3R stereoisomer). It is an antifungal drug used for the topical treatment of onychomycosis (a nail infection caused mainly by dermatophytes).	3.51	1	0	conazole antifungal drug; olefinic compound; organofluorine compound; piperidines; tertiary alcohol; tertiary amino compound; triazole antifungal drug	EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
terbinafine [no description available]	6.43	20	0	acetylenic compound; allylamine antifungal drug; enyne; naphthalenes; tertiary amine	EC 1.14.13.132 (squalene monooxygenase) inhibitor; P450 inhibitor; sterol biosynthesis inhibitor
cancidas [no description available]	3.43	7	0
latoconazole latoconazole: RN refers to cpd without isomeric designation; latoconazole is (E)-isomer; structure given in first source	2.41	1	0	conazole antifungal drug; imidazole antifungal drug
tak 456 TAK 456: structure in first source	3.51	1	0
nnd 502 luliconazole: structure in first source	2.41	1	0	dichlorobenzene
2-(2,4-difluorophenyl)-3-(4-(4-(2-(4-trifluoromethoxybenzyl)-2h-1,2,4-triazol-3-one-4-yl)phenyl)piperazin-1-yl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol Syn 2869: structure in first source	3.51	1	0
galactomannan galactomannan: a galectin inhibitor. galactomannan : A heteroglycan consisting of a mannan backbone with galactose side groups.	2.02	1	0	oligosaccharide
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	6.82	31	0	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	2.05	1	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
dexmedetomidine [no description available]	2.11	1	0	medetomidine	alpha-adrenergic agonist; analgesic; non-narcotic analgesic; sedative
r-120758 R-120758: structure in first source	3.51	1	0
isavuconazole isavuconazole : A 1,3-thiazole that is butan-2-ol which is substituted at positions 1, 2, and 3 by 1,2,4-triazol-1-yl, 2,5-difluorophenyl, and 4-(p-cyanophenyl)-1,3-thiazol-2-yl groups, respectively. It is an antifungal drug used for the treatment of invasive aspergillosis and invasive mucormycosis.	10.91	7	0	1,3-thiazoles; conazole antifungal drug; difluorobenzene; nitrile; tertiary alcohol; triazole antifungal drug	EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; ergosterol biosynthesis inhibitor; orphan drug
oxadiazoles Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.	2.08	1	0
nystatin a1 Nystatin: Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.. nystatin : A heterogeneous mixture of polyene compounds produced by cultures of Streptomyces noursei. It mainly consists of three biologically active components designated nystatin A1, nystatin A2, and nystatin A3. It is used to treat oral and dermal fungal infections.. nystatin A1 : A polyene macrolide antibiotic; part of the nystatin complex produced by several Streptomyces species. It is an antifungal antibiotic used for the treatment of topical fungal infections caused by a broad spectrum of fungal pathogens comprising yeast-like and filamentous species.	2.07	1	0	nystatins
aminocandin aminocandin: a lipopeptide belonging to the echinocandin class of antifungal compounds; inhibits glucan synthase. aminocandin : A member of the family of echinocandins that shows broad-spectrum in vitro activity against Aspergillus and Candida spp.	4.07	2	0	aromatic ether; echinocandin; homodetic cyclic peptide	antiinfective agent
mannans [no description available]	2.02	1	0
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	2.6	1	0
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	2.05	1	0
echinocandin b echinocandin B: a cyclic hexapeptide echinocandin antibiotic isolated from Aspergillus nidulans var. echinulatus with specific anti-yeast activity; inhibits beta-1,3-glucan synthesis. echinocandin B : A cyclic hexapeptide echinocandin antibiotic isolated from Aspergillus nidulans var. echinulatus with specific anti-yeast activity.	2.02	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Aspergillus Infection [description not available]	0	5.41	14	0
Candida Infection [description not available]	0	6.24	21	0
Aspergillosis Infections with fungi of the genus ASPERGILLUS.	0	5.41	14	0
Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)	0	11.24	21	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	3.42	7	0
Sporothrix brasiliensis Infection [description not available]	0	2.04	1	0
Sporotrichosis The commonest and least serious of the deep mycoses, characterized by nodular lesions of the cutaneous and subcutaneous tissues. It is caused by inhalation of contaminated dust or by infection of a wound with SPOROTHRIX.	0	2.04	1	0
Fungemia The presence of fungi circulating in the blood. Opportunistic fungal sepsis is seen most often in immunosuppressed patients with severe neutropenia or in postoperative patients with intravenous catheters and usually follows prolonged antibiotic therapy.	0	2.71	3	0
Fungal Diseases [description not available]	0	6.27	13	0
Mycoses Diseases caused by FUNGI.	1	8.27	13	0
American Trypanosomiasis [description not available]	0	9.19	16	5
Chagas Disease Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.	0	9.19	16	5
Alloxan Diabetes [description not available]	0	2.05	1	0
Mucorales Infection [description not available]	0	2.05	1	0
Mucormycosis Infection in humans and animals caused by any fungus in the order MUCORALES (e.g., RHIZOPUS; MUCOR; CUNNINGHAMELLA; APOPHYSOMYCES; ABSIDIA; SAKSENAEA and RHIZOMUCOR) There are many clinical types associated with infection including central nervous system, lung, gastrointestinal tract, skin, orbit and paranasal sinuses. In humans, it usually occurs as an OPPORTUNISTIC INFECTION.	0	2.05	1	0
Neglected Diseases Diseases that are underfunded and have low name recognition but are major burdens in less developed countries. The World Health Organization has designated six tropical infectious diseases as being neglected in industrialized countries that are endemic in many developing countries (HELMINTHIASIS; LEPROSY; LYMPHATIC FILARIASIS; ONCHOCERCIASIS; SCHISTOSOMIASIS; and TRACHOMA).	0	2.93	3	0
Actinomycetoma [description not available]	0	3.11	3	0
Mycetoma A chronic progressive subcutaneous infection caused by species of fungi (eumycetoma), or actinomycetes (actinomycetoma). It is characterized by tumefaction, abscesses, and tumor-like granules representing microcolonies of pathogens, such as MADURELLA fungi and bacteria ACTINOMYCETES, with different grain colors.	0	3.11	3	0
Dermatophytoses [description not available]	0	2.98	3	0
Tinea Fungal infection of keratinized tissues such as hair, skin and nails. The main causative fungi include MICROSPORUM; TRICHOPHYTON; and EPIDERMOPHYTON.	0	7.98	3	0
Infection [description not available]	0	2.25	1	0
Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.	0	2.25	1	0
Dermatomycoses Superficial infections of the skin or its appendages by any of various fungi.	0	7.87	3	0
Parasitemia The presence of parasites (especially malarial parasites) in the blood. (Dorland, 27th ed)	0	2.25	1	0
Adverse Drug Event [description not available]	0	4.48	1	1
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	0	4.48	1	1
Nail Fungus [description not available]	0	8.1	7	3
Onychomycosis A fungal infection of the nail, usually caused by DERMATOPHYTES; YEASTS; or nondermatophyte MOLDS.	0	8.1	7	3
Foot Dermatoses Skin diseases of the foot, general or unspecified.	0	6.53	3	2
Canine Diseases [description not available]	0	2.25	1	0
Chloasma [description not available]	0	2.21	1	0
Hand Dermatosis [description not available]	0	2.61	2	0
Hand Dermatoses Skin diseases involving the HANDS.	0	2.61	2	0
Melanosis Disorders of increased melanin pigmentation that develop without preceding inflammatory disease.	0	2.21	1	0
Allergic Bronchopulmonary Mycosis [description not available]	0	2.1	1	0
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	0	2.45	2	0
Breast Cancer [description not available]	0	2.11	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	0	2.11	1	0
Candidiasis, Invasive An important nosocomial fungal infection with species of the genus CANDIDA, most frequently CANDIDA ALBICANS. Invasive candidiasis occurs when candidiasis goes beyond a superficial infection and manifests as CANDIDEMIA, deep tissue infection, or disseminated disease with deep organ involvement.	0	2.98	1	0
Fungal Lung Diseases [description not available]	0	2.93	4	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	2.02	1	0
Allergic Bronchopulmonary Aspergilloses [description not available]	0	2.02	1	0
Aspergillosis, Allergic Bronchopulmonary Hypersensitivity reaction (ALLERGIC REACTION) to fungus ASPERGILLUS in an individual with long-standing BRONCHIAL ASTHMA. It is characterized by pulmonary infiltrates, EOSINOPHILIA, elevated serum IMMUNOGLOBULIN E, and skin reactivity to Aspergillus antigen.	0	2.02	1	0
C gattii Infection [description not available]	0	4.02	5	0
Cryptococcosis Fungal infection caused by genus CRYPTOCOCCUS.	0	4.02	5	0
Brain Disorders [description not available]	0	1.99	1	0
Moniliasis, Oral [description not available]	0	1.99	1	0
Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.	0	1.99	1	0
Candidiasis, Oral Infection of the mucous membranes of the mouth by a fungus of the genus CANDIDA. (Dorland, 27th ed)	0	1.99	1	0
AIDS-Related Opportunistic Infections Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.	0	2.91	1	0
Candidiasis, Chronic Mucocutaneous A clinical syndrome characterized by development, usually in infancy or childhood, of a chronic, often widespread candidiasis of skin, nails, and mucous membranes. It may be secondary to one of the immunodeficiency syndromes, inherited as an autosomal recessive trait, or associated with defects in cell-mediated immunity, endocrine disorders, dental stomatitis, or malignancy.	0	2	1	0
Histoplasma capsulatum Infection [description not available]	0	2.01	1	0
Histoplasmosis Infection resulting from exposure to the fungus HISTOPLASMA. It is worldwide in distribution and particularly common in the central and eastern states, especially areas around the Ohio and Mississippi River valleys.	0	7.01	1	0
Benign Neoplasms [description not available]	0	2.01	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	2.01	1	0

ravuconazole

Description

Cross-References

Synonyms (53)

Research Excerpts

Overview

Effects

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (4)

Drug Classes (5)

Protein Targets (2)

Inhibition Measurements

Biological Processes (41)

Molecular Functions (34)

Ceullar Components (8)

Bioassays (248)

Research

Studies (121)

Market Indicators

Research Demand Index: 33.85

Study Types

ravuconazole

Description

Related Flora

Cross-References

Synonyms (53)

Research Excerpts

Overview

Effects

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (4)

Drug Classes (5)

Protein Targets (2)

Inhibition Measurements

Biological Processes (41)

Molecular Functions (34)

Ceullar Components (8)

Bioassays (248)

Research

Studies (121)

Market Indicators

Research Demand Index: 33.85

Study Types

Related Drugs (58)

Related Conditions (55)